BALLERUP, Denmark — October 1, 2026
LEO Pharma A/S presented new data on delgocitinib cream in chronic hand eczema (CHE) at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna. Interim results from the German REACHED study provided the first real-world evidence on delgocitinib cream in adults with moderate to severe CHE. After eight weeks of treatment, 28.6% of patients were assessed as clear or almost clear, compared with none at baseline. Mean Hand Eczema Severity Index (HECSI) scores decreased from 62.4 to 30.8, while 35.5% of patients achieved at least a 75% improvement in HECSI.
Delgocitinib Improves Itch, Pain and Quality of Life in Adolescents
New post hoc analyses from the Phase III DELTA TEEN trial showed improvements in daily itch and pain symptoms among adolescents aged 12–17 with moderate to severe CHE. Mean reductions in Hand Eczema Symptom Diary itch and pain scores were greater with delgocitinib cream than with cream vehicle at Day 1 and during the first two weeks of treatment. At Week 16, 27.0% of adolescents receiving delgocitinib reported no impact of CHE on quality of life, measured by a Children’s Dermatology Life Quality Index score of 0, compared with 0% receiving vehicle. The proportion reporting a large or very large quality-of-life impact also declined from 21.6% at baseline to 4.1% at Week 16 with delgocitinib.
REACHED Data Show Improvements Across Multiple CHE Measures
The German REACHED study demonstrated improvements across disease severity, quality of life and patient-reported symptoms after eight weeks of treatment. Mean Dermatology Life Quality Index scores decreased from 14.5 to 7.9, while mean itch and pain numerical rating scores decreased by 2.1 and 2.7 points, respectively. All reported adverse events were non-serious, with all but one considered mild or moderate. The prospective, non-interventional study is evaluating delgocitinib cream 20 mg/g in adults with moderate to severe CHE in routine clinical practice.
Advertisement
Delgocitinib Continues Development in Chronic Hand Eczema
Delgocitinib is a topical non-steroidal pan-Janus kinase (JAK) inhibitor designed to inhibit JAK-STAT signaling involved in the pathogenesis of CHE. The treatment is marketed as Anzupgo® and is approved in multiple markets, including the European Union, United Kingdom, Switzerland, Canada, Australia, South Korea, the United Arab Emirates and the United States for moderate to severe CHE in adults under specified treatment conditions. The new EADV data expand the clinical evidence for delgocitinib across both adults and adolescents and include findings from controlled clinical trials and routine clinical practice. LEO Pharma continues to evaluate the therapy’s potential to address the symptoms and quality-of-life burden associated with chronic hand eczema.
Source: LEO Pharma, press release
